Register for free to listen to this article
Listen with Speechify
0:00
1:00
GERMANTOWN, Md.—QIAGEN announced May 3 that it has joinedthe Point-of-Care Diagnostics (POC Dx) Initiative led by the Bill & MelindaGates Foundation and Grand Challenges Canada to create a new moleculardiagnostics platform to serve resource-poor regions of the world.
 
 
QIAGEN is joining more than 20 nonprofit, academic andcorporate organizations in the POC Dx Initiative, which aims to catalyze a"diagnostics revolution" for the developing world. The goal of the initiativeis to create new platforms that enable high-quality, low-cost point-of-carediagnosis, and to make systematic and sustainable improvements in healthcare inthe developing world.
 
 
In a press release announcing its participation, QIAGENnoted that the development of affordable and portable diagnostic systems is oneof the 16 Grand Challenges in Global Health, an initiative that seeks toenhance healthcare in the world's poorest countries, and the company hasalready started the development of a portable instrument based on its advancedmolecular testing technologies for point-of-need applications.
 
 
QIAGEN's role in the initiative is to develop aneasy-to-use, portable molecular testing device that can perform diagnostictests in the field, far from hospital or laboratory infrastructure. This taskalso encompasses the creation of a corresponding assay technology suited foruse in low-resource settings. This project is part of the technologydevelopment phase of the POC Dx initiative, which will then integratesuccessful technologies into a multifunctional point-of-care platform.
 
 
"The new low-cost portable testing devices currently underdevelopment are intended to enable reliable, quick diagnosis and timeliertreatment of patients," said Dr. Ellen Sheets, chief medical officer of QIAGEN,in a statement. "We believe that modern diagnostic technologies can have a verysignificant positive impact on developing countries, helping to save lives,reduce economic impacts, and curtail the spread of infectious diseases."

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue